● Recruiting

Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

Condition: Multiple Myeloma · Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseN/A

Planned participants260

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

We propose to conduct an ancillary prospective evaluation of the impact of Dara-Len-Dex discontinuation after 2 years, on the persistence of MRD negativity in patients that were MRD negative at 2 years.

This description comes directly from the study's public registry record.

Talk to the study team

Mohamad MOHTY, PUPH · + 33 149 28 26 20 · mohamad.mohty@inserm.fr

Florent MALARD, MD · +33 149 28 09 68 · malardf@yahoo.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Hematology, Hospital Saint Antoine

Paris, France

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05203003